Isomorphic Labs, the AI-focused drug developer backed by Alphabet, raised $5 billion in a private Series C financing led by Greenoaks and Sequoia Capital, BioPharma Dive reported. The round includes participation from existing investors and new backers including Andreessen Horowitz, following a $2.1 billion Series B announced in May. The company said the financing is intended to move from AI platform development toward bringing medicines into the clinic, with plans to expand into additional biology areas. The size of the round underscores continued investor appetite for “AI-first” drug discovery despite broader tech-market volatility.
Get the Daily Brief